Core Viewpoint - The company Valiant Pharmaceuticals (维立志博-B, 09887) experienced a significant stock price fluctuation, initially dropping but later increasing by over 5% after the announcement of its core product, LBL-024, receiving orphan drug designation from the European Commission for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1: Product Development - LBL-024 has reached an important milestone in its global development process by obtaining orphan drug status, which provides various incentives including 10 years of market exclusivity and regulatory fee waivers [1] - The product has demonstrated first-in-class (FIC) or best-in-class (BIC) potential in Phase II or registration clinical trials for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC [1] Group 2: Clinical Trials and Approvals - LBL-024 is an antibody that targets both PD-L1 and 4-1BB, showing promising efficacy signals in two clinical trials conducted in China [1] - The company is set to receive approval from the National Medical Products Administration (NMPA) in April 2024 to conduct a single-arm registration clinical trial, with breakthrough therapy designation for the treatment of advanced extra-pulmonary neuroendocrine carcinoma expected in October 2024 [1]

Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 5%, reaching 55.2 HKD, following the announcement of orphan drug designation for its drug Valiant (Oparatuzumab, LBL-024) by the European Commission [1] Group 1 - On January 22, Valiant Pharmaceuticals-B announced that the European Commission granted orphan drug designation for its PD-L1/4-1BB bispecific antibody, Valiant, for the treatment of pulmonary neuroendocrine carcinoma [1] - This designation is a significant milestone, marking the second orphan drug designation for Valiant after receiving similar recognition from the U.S. Food and Drug Administration (FDA) [1] - The announcement reflects Valiant's progress in its global development efforts [1]

Core Viewpoint - The announcement by Vili Zhibo-B (09887) regarding the orphan drug designation for LBL-024 (Opalizumab) for the treatment of pulmonary neuroendocrine carcinoma marks a significant milestone in its global development process, following a similar designation from the FDA [1] Group 1 - The European Commission (EC) granted orphan drug designation for LBL-024 on January 9, 2026, which is the second such designation after receiving FDA recognition [1] - Orphan drugs are defined by the EC as those intended for the diagnosis, prevention, or treatment of life-threatening or chronically debilitating conditions with a prevalence of less than 5 in 10,000 in the EU [2] Group 2 - The orphan drug designation provides several key incentives, including scientific advice from the European Medicines Agency (EMA) on various aspects of research design [2] - It grants a 10-year market exclusivity period in the EU from the date of marketing authorization, preventing other companies from approving similar drugs for the same indication during this time [2] - Additional benefits include fee reductions for regulatory processes and potential funding from the EC and Horizon Europe, as well as extra incentives for micro, small, and medium-sized enterprises [2]

1月12日晚，万邦德（002082）和海翔药业（002099）双双发布公告，双方同意围绕渐冻症适应症，发 挥各自优势，开展相关合作。 公告显示，1月12日，万邦德全资子公司万邦德制药集团有限公司(下称"万邦德制药")与海翔药业签订 了《创新药合作协议》，致力于通过本次合作，高效推进WP205产品(渐冻症适应症，下同)的研发，最 终实现该产品在全球主要医药市场(包括但不限于中国、美国、日本等)获得用于治疗渐冻症的监管批准 并成功商业化。 双方初期合作，将聚焦于万邦德制药已获孤儿药认定的WP205产品研发和商业化，后续双方还将就万邦 德制药针对melanocortinreceptor(MCR)靶点的小分子环肽激动剂开展原料与制剂等方面的合作。 万邦德制药主要从事现代中药、化学原料药及化学制剂的研发、生产和销售。在治疗肌萎缩侧索硬化 (下称"ALS"，也称渐冻症)领域，万邦德制药布局了自主研发项目WP205产品，已获得美国FDA针对渐 冻症的孤儿药认定(申请号为DRU-2024-10575)，并申报相关制剂专利。此外，该公司还布局了针对 melanocortinreceptor(MCR)靶点的小分子环肽激动剂，矢志 ...

Core Viewpoint - Corning Jereh's Envafolimab has received Orphan Drug Designation from the FDA for the treatment of gastric cancer and gastroesophageal junction cancer, marking its third orphan drug designation after advanced biliary tract cancer and soft tissue sarcoma [1][2]. Group 1: Product Development - Envafolimab is a subcutaneously administered PD-L1 single-domain antibody Fc fusion protein developed by Corning Jereh [2][3]. - The product has been in collaboration with Sorrento Therapeutics since 2016, with a strategic partnership established in March 2020 involving Corning Jereh, Sorrento Therapeutics, and Ascletis Pharma [2][3]. - Envafolimab was approved for marketing in China in November 2021 for use in unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors [2][3]. Group 2: Regulatory Milestones - The FDA's Orphan Drug Designation for Envafolimab is significant as it provides incentives for the development of treatments for rare diseases [1]. - Prior to this designation, Envafolimab had already received Breakthrough Therapy Designation from the National Medical Products Administration (NMPA) for treating high tumor mutational burden (TMB-H) unresectable or metastatic solid tumors [2][3].

Core Viewpoint - Sidley Pharmaceuticals (01244) announced that its commercial product Envita (generic name: Envafolimab injection, original research code: KN035) has officially received orphan drug designation for the indications of gastric cancer and gastroesophageal junction cancer, marking the third orphan drug indication approval following cholangiocarcinoma and soft tissue sarcoma [1] Group 1 - The approval is based on the results of the Phase II clinical study of Envita in patients with advanced gastric/gastroesophageal junction adenocarcinoma, which demonstrated clear antitumor efficacy [1] - The objective response rate of the combination with the FOLFOX regimen reached 60%, and the disease control rate was as high as 100% [1] - The safety and tolerability of the treatment were good, with no adverse events leading to treatment discontinuation or death reported [1]

Core Viewpoint - Zai Jian Pharmaceutical announced that its investigational product ZG006 has received orphan drug designation from the FDA for the treatment of neuroendocrine cancer, marking it as the first trispecific antibody targeting the DLL3 antigen with potential to be a best-in-class molecule [1] Group 1: Product Development - ZG006 is the first trispecific antibody targeting the DLL3 antigen globally [1] - The orphan drug designation will provide ZG006 with policy support for further research, registration, and commercialization in the U.S. [1] Group 2: Benefits of Orphan Drug Designation - The designation includes benefits such as tax credits for clinical trial costs, waiver of new drug application fees, and seven years of market exclusivity [1]

Core Points - The company announced that its investigational product ZG006 has received Orphan-drug Designation from the FDA for the treatment of neuroendocrine cancer [1] - ZG006 is a trispecific antibody drug developed through the company's dual/multi-specific antibody research platform [1] - The product has obtained clinical trial approval from both the FDA and China's NMPA, and has been included in breakthrough therapy designations by the respective regulatory authorities [1]

Core Insights - Wanbangde's subsidiary has made significant progress in the internationalization of its pemphigus treatment, successfully winning the first position in the 11th national drug procurement for its bromhexine hydrochloride injection [1] - The company submitted an orphan drug designation application for WP203A (alfanotide) to the FDA, which has been confirmed, marking a key step in its international strategy for pemphigus treatment [1][2] - Pemphigus is a rare autoimmune disease characterized by severe blistering and erosion of the skin and mucous membranes, primarily affecting the elderly [1][2] Industry Overview - The global prevalence of pemphigus is estimated to be between 1 to 50 cases per million, translating to approximately 70,000 to 2.1 million patients worldwide, with the most common type being pemphigus vulgaris [2] - Current treatments mainly involve corticosteroids and immunosuppressants, which have significant side effects, while biologics like rituximab and eculizumab are effective but expensive and require intravenous administration [2] - There are about 10 to 15 new drugs in clinical stages globally for pemphigus, including Wanbangde's WP203A [2] Regulatory and Market Implications - The orphan drug designation by the FDA provides various incentives for drug development, including tax credits for clinical trial costs, waiver of new drug application fees, and seven years of market exclusivity post-approval [2][3] - The global market for pemphigus drugs is expected to reach hundreds of billions of RMB, positioning the development of WP203A as a high-quality opportunity in the rare disease sector [3] - Wanbangde aims to transition from generic drugs to innovative drugs, with WP203A potentially becoming a significant player in the pemphigus treatment market due to its differentiated mechanism and international strategy [3]

Core Viewpoint - Wanbangde's subsidiary has received orphan drug designation from the FDA for WP203A (alfanorelin) to treat pemphigus [2] Group 1: Company Announcement - Wanbangde announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has received a recognition letter from the FDA [2] - The orphan drug designation is specifically for WP203A (alfanorelin), which is a synthetic agonist of the melanocortin-1 receptor (MC1R) [2] - Alfanorelin exerts its anti-inflammatory and immunomodulatory effects by activating the MC1R receptor [2] Group 2: Current Applications - Alfanorelin has already been successfully applied in the treatment of erythropoietic protoporphyria (EPP) [2]